A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy

NCT04291781 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary IgA Nephropathy

Interventions

BIOLOGICAL: RC18 160mg
BIOLOGICAL: RC18 240mg
BIOLOGICAL: placebo

Sponsor

RemeGen Co., Ltd.